$CDNA stock has now fallen 8% today, according to our price data from Polygon. There has been approximately $1,757,375 of trading volume.
Here is what we see in our data on $CDNA (you can track the company live on Quiver's $CDNA stock page):
$CDNA Insider Trading Activity
$CDNA insiders have traded $CDNA stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CDNA stock by insiders over the last 6 months:
- JOHN WALTER JR HANNA (President and CEO) has made 0 purchases and 3 sales selling 29,636 shares for an estimated $626,026.
- JEFFREY ADAM NOVACK (Secretary and General Counsel) has made 0 purchases and 4 sales selling 14,422 shares for an estimated $272,813.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CDNA Hedge Fund Activity
We have seen 101 institutional investors add shares of $CDNA stock to their portfolio, and 126 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,765,981 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $25,677,363
- OPHIR ASSET MANAGEMENT PTY LTD removed 1,272,514 shares (-57.9%) from their portfolio in Q4 2025, for an estimated $23,974,163
- NEXT CENTURY GROWTH INVESTORS LLC removed 1,125,454 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $16,364,101
- BOSTON PARTNERS added 870,574 shares (+2776.5%) to their portfolio in Q4 2025, for an estimated $16,401,614
- FRED ALGER MANAGEMENT, LLC removed 754,275 shares (-81.2%) from their portfolio in Q4 2025, for an estimated $14,210,541
- BRAIDWELL LP removed 597,561 shares (-27.4%) from their portfolio in Q4 2025, for an estimated $11,258,049
- KENT LAKE PR LLC added 550,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $7,996,999
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CDNA Government Contracts
We have seen $4,919,516 of award payments to $CDNA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TRANSPLANT TESTING KITS: $849,384
- LAB TESTS FOR POST TRANSPLANT ORGAN REJECTION: $522,483
- GENETIC BLOOD TESTING FOR TRANSPLANT PATIENTS (ALLOMAP AND ALLOSURE): $491,742
- GENETIC BLOOD TESTING FOR TRANSPLANT PATIENTS (ALLOMAP AND ALLOSURE): $250,538
- ALLOMAP AND ALLOSURE POST HEART TRANSPLANT REJECTION SURVEILLANCE TESTS SERVICES: $244,595
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
$CDNA Analyst Ratings
Wall Street analysts have issued reports on $CDNA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for $CDNA, check out Quiver Quantitative's $CDNA forecast page.
$CDNA Price Targets
Multiple analysts have issued price targets for $CDNA recently. We have seen 2 analysts offer price targets for $CDNA in the last 6 months, with a median target of $21.5.
Here are some recent targets:
- Brandon Couillard from Wells Fargo set a target price of $18.0 on 12/15/2025
- Mark Massaro from BTIG set a target price of $25.0 on 11/06/2025
You can track data on $CDNA on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
